Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
a technology of basal metabolic rate and katp channel, which is applied in the direction of organic active ingredients, peptide/protein ingredients, anhydride/acid/halide active ingredients, etc., can solve the problems of undesirable side effects of many of the aforementioned drugs currently used to treat pws
Inactive Publication Date: 2016-08-11
SEDOGEN
View PDF1 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
This approach allows for reduced side effects, improved energy levels, and stabilization of IGF-1 levels, enabling effective treatment of PWS without the full dosage of traditional medications, while also managing nutritional phases and blood ketone levels.
Problems solved by technology
Many of the aforementioned drugs that are currently used to treat PWS have undesirable side effects.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
example 1
Treating PWS
[0158]This example shows how a KATP channel opener addresses abnormalities observed in patients with PWS. In particular, the channel opener diazoxide may hyperpolarize hypothalamic neurons in a manner similar to leptin.
[0159]Diazoxide has now been prescribed at low doses for two infants with PWS, both of which had experienced hypoglycemic episodes. One infant in PWS nutritional phase 1a transitioning to phase 1b was started at 0.5 mg / kg BID of diazoxide at eight months of age, increasing to 1 mg / kg BID. No changes in blood pressure or heart rate were observed, and no signs of edema were present. Within two weeks of starting diazoxide, the infant's strong narcoleptic response to solid foods had been virtually eliminated. Subjectively, her energy level and stamina also improved, and her therapists documented her significant progress. The infant's baseline IGF-1 levels were 152 ng / mL while on 0.8 mg QD of Genotropin. Around three weeks after starting diazoxide levels, the I...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| spectrum disorder | aaaaa | aaaaa |
| Pervasive Developmental Disorder | aaaaa | aaaaa |
| resistance | aaaaa | aaaaa |
Login to View More
Abstract
This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels.
Description
FIELD OF THE INVENTION[0001]This invention relates to treating Prader-Willi Syndrome (PWS) and conditions affecting basal metabolic rate using a KATP channel opener. The KATP channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric / mood stabilizing medication, which may allow the dose of these other therapies to be reduced relative to the dose that would otherwise be given to a patient with PWS in the absence of the KATP channel opener (e.g., baseline dose). The KATP channel opener may also obviate the need for the use of the other therapies used to treat PWS, such that PWS may be treated without human growth hormone, a wakefulness promoting agent, or a psychiatric / mood stabilizing medication. The KATP channel opener dosage may also be administered according to the PWS nutritional phase of a patient. The KATP channel opener may also be administered to prevent the PWS patient's PWS nutri...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/549A61K45/06
CPCA61K38/11A61K38/27A61K31/549A61K31/00A61K45/06A61K31/522A61K31/198A61K31/19A61K31/145A61K2300/00A61K38/095
Inventor COTTER, SARA
Owner SEDOGEN